♥

Caplin Point Laboratories Limited

ISIN : INE475E01026
NSE : CAPLIPOINT
BSE : 524742
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 59.90
EPS (TTM) : 62.59
Price to Earning (P/E) : 33.39
Book Value : 293.21
Price to Bookvalue (P/B) : 6.82
Dividend Yield : 0 %
Return on Equity (ROE) : 22.97 %
Return on Capital Employed (ROCE) : 26.92 %

Caplin Point share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	1573.65 - 1567.85 -0.4 %
Low / High	1510 - 1573.7 4.2 %
Trade Volume	7,749
52 Week Low / High	1502.45 - 2396.95 59.5 %

YOU MAY ALSO LIKE

Share Market basics for beginners
Share Market jargons in simple terms
Stock market course tutorial
Stock Market Investment Course explained in simple words.
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR CAPLIN POINT LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	3392.4	3463.3	3590.5	3720.7	3892.8	3953.2	4100.6	4355	4532.2	4589.6
Total Income	3507.5	3602.7	3755.3	3862.2	4006.8	4073.6	4304.9	4526.8	4705.1	4775.2
Total Expenditure	2393	2441.5	2534.7	2627	2653.5	2687.9	2726.6	2932.2	3079.9	3071.5
Other Income	115.1	139.4	164.8	141.5	114	120.4	204.3	171.8	172.9	185.6
Operating Profit	1114.5	1161.2	1220.6	1235.2	1353.3	1385.7	1578.3	1594.6	1625.2	1703.7
Interest	0.8	0.6	1.4	3.6	2.3	2.8	1.8	1.7	1.5	0.5
PBDT	1113.7	1160.6	1219.2	1231.6	1351	1382.9	1576.5	1592.9	1623.7	1703.2
Depreciation	114.5	109.7	114.6	114.3	111.3	113.8	117.6	139	164	159.6
Profit Before Tax	999.2	1050.9	1104.6	1117.3	1239.7	1269.1	1458.9	1453.9	1459.7	1543.6
Tax	190.9	187.8	184.2	143.5	228.1	227.6	298.6	255.9	248	294.6
Profit After Tax	808.3	863.1	920.4	973.8	1011.6	1041.5	1160.3	1198	1211.7	1249
Net Profit	808.3	863.1	920.4	973.8	1011.6	1041.5	1160.3	1198	1211.7	1249
Equity Capital	151.6	151.6	151.6	151.8	151.8	151.9	151.9	151.9	151.9	152
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	10.43	11.21	12.09	12.84	13.45	13.62	15.12	15.43	16.01	16.31
Diluted Eps After Extraordinary Items	10.33	11.12	11.99	12.75	13.33	13.55	15.06	15.39	15.9	16.24
Diluted Eps Before Extraordinary Items	10.33	11.12	11.99	12.75	13.33	13.55	15.06	15.39	15.9	16.24

STANDALONE QUARTERLY RESULT FOR CAPLIN POINT LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1119.4	1163.9	1369.5	1306	1446.7	1736.6	1792.2	1328.3	1393.8	1856.4
Total Income	1222	1513.6	1594	1599.6	1568.9	2009.3	2037.1	1507.3	1755.6	2071.4
Total Expenditure	735.3	702.8	795.3	790.9	798	970.4	897.7	695.1	817	1042.6
Other Income	102.6	349.7	224.5	293.6	122.2	272.7	244.9	179	361.8	215
Operating Profit	486.7	810.8	798.7	808.7	770.9	1038.9	1139.4	812.2	938.6	1028.8
Interest	0.2	0.1	0.4	0.4	0.3	0.3	0.2	0.3	0.2	0.2
PBDT	486.5	810.7	798.3	808.3	770.6	1038.6	1139.2	811.9	938.4	1028.6
Depreciation	69.5	63.7	65.1	64.7	62.9	66.7	67.2	67.6	69.3	61.8
Profit Before Tax	417	747	733.2	743.6	707.7	971.9	1072	744.3	869.1	966.8
Tax	126.8	114.6	158.1	151.9	164.4	209.2	251	189.8	170.3	241.4
Profit After Tax	290.2	632.4	575.1	591.7	543.3	762.7	821	554.5	698.8	725.4
Net Profit	290.2	632.4	575.1	591.7	543.3	762.7	821	554.5	698.8	725.4
Equity Capital	151.6	151.6	151.6	151.8	151.8	151.9	151.9	151.9	151.9	152
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	3.83	8.34	7.59	7.8	7.16	10.04	10.81	7.3	9.2	9.54
Diluted Eps After Extraordinary Items	3.79	8.27	7.52	7.74	7.09	9.99	10.76	7.29	9.14	9.5
Diluted Eps Before Extraordinary Items	3.79	8.27	7.52	7.74	7.09	9.99	10.76	7.29	9.14	9.5

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR CAPLIN POINT LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	12694.1	14667.3	16941
Total Income	13081.6	15227.1	17610.4
Total Expenditure	8747.4	10256.7	11426.6
Other Income	387.5	559.8	669.4
Operating Profit	4334.2	4970.4	6183.8
Interest	7	7.8	7.8
PBDT	4327.2	4962.6	6176
Depreciation	469	449.9	534.4
Profit Before Tax	3858.2	4512.7	5641.6
Tax	773.7	743.6	1030.1
Profit After Tax	3084.5	3769.1	4611.5
Net Profit	3084.5	3769.1	4611.5
Equity Capital	151.6	151.8	151.9
Face Value (IN RS)	2	2	2
Reserves	14687.7	18653	23005.1
Calculated EPS	39.56	49.57	60.18
Diluted Eps After Extraordinary Items	39.26	49.18	59.9
Diluted Eps Before Extraordinary Items	39.26	49.18	59.9

STANDALONE ANNUAL RESULT FOR CAPLIN POINT LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	5280.6	5286.1	6250.9
Total Income	5846.1	6276.1	7309.3
Total Expenditure	3084.4	3086.9	3380.1
Other Income	565.5	990	1058.4
Operating Profit	2761.7	3189.2	3929.2
Interest	0.9	1.2	1
PBDT	2760.8	3188	3928.2
Depreciation	257.7	256.5	270.8
Profit Before Tax	2503.1	2931.5	3657.4
Tax	624.4	588.9	820.3
Profit After Tax	1878.7	2342.6	2837.1
Net Profit	1878.7	2342.6	2837.1
Equity Capital	151.6	151.8	151.9
Face Value (IN RS)	2	2	2
Reserves	9154.9	11247.3	13749.6
Calculated EPS	24.79	30.86	37.35
Diluted Eps After Extraordinary Items	24.6	30.62	37.18
Diluted Eps Before Extraordinary Items	24.6	30.62	37.18

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1061.29 Cr	1269.41 Cr	1466.73 Cr	1694.1 Cr
Sales	1010.77 Cr	1210.49 Cr	1389.7 Cr	1601.55 Cr
Processing Charges / Service Income	37.48 Cr	52.52 Cr	64.12 Cr	75.23 Cr
Net Sales	1061.29 Cr	1269.41 Cr	1466.73 Cr	1694.1 Cr
Increase/Decrease in Stock	82.35 Cr	-31.92 Cr	-46.94 Cr	-74.55 Cr
Raw Material Consumed	389.39 Cr	589.43 Cr	710.15 Cr	798.73 Cr
Opening Raw Materials	9.81 Cr	21.91 Cr	32.03 Cr	38.87 Cr
Purchases Raw Materials	141.92 Cr	202.43 Cr	213.12 Cr	241.59 Cr
Closing Raw Materials	21.91 Cr	32.03 Cr	38.87 Cr	40.65 Cr
Other Direct Purchases / Brought in cost	259.57 Cr	397.12 Cr	503.87 Cr	558.92 Cr
Power & Fuel Cost	16.36 Cr	21.4 Cr	25.53 Cr	33.57 Cr
Electricity & Power	16.36 Cr	21.4 Cr	25.53 Cr	33.57 Cr
Employee Cost	101.96 Cr	114.74 Cr	136.12 Cr	142.66 Cr
Salaries, Wages & Bonus	83.16 Cr	92.31 Cr	113.26 Cr	118.36 Cr
Contributions to EPF & Pension Funds	7.47 Cr	8.62 Cr	8.22 Cr	10.62 Cr
Workmen and Staff Welfare Expenses	5.98 Cr	7.14 Cr	8.08 Cr	11.26 Cr
Other Manufacturing Expenses	69.85 Cr	82.01 Cr	90.99 Cr	117.73 Cr
Processing Charges	3.91 Cr	4.92 Cr	5.76 Cr	6.9 Cr
Repairs and Maintenance	8.89 Cr	14.88 Cr	15.98 Cr	31.95 Cr
General and Administration Expenses	38.54 Cr	49.16 Cr	62.98 Cr	89.41 Cr
Rent , Rates & Taxes	17.26 Cr	20.14 Cr	33.28 Cr	42.87 Cr
Insurance	1.82 Cr	2 Cr	2.33 Cr	2.92 Cr
Professional and legal fees	12.61 Cr	18.42 Cr	14.94 Cr	10.84 Cr
Traveling and conveyance	2.72 Cr	3.58 Cr	4.94 Cr	6.9 Cr
Selling and Distribution Expenses	18.03 Cr	27.51 Cr	18.78 Cr	28.44 Cr
Freight and Forwarding	7.14 Cr	17.08 Cr	10.35 Cr	9.54 Cr
Miscellaneous Expenses	16.16 Cr	22.55 Cr	28.6 Cr	6.66 Cr
Loss on disposal of fixed assets(net)	60.05 Lk	31 Lk	70 Lk	92 Lk
Loss on sale of non-trade current investments	0	14 Lk	0	0
Total Expenditure	732.65 Cr	874.88 Cr	1026.21 Cr	1142.65 Cr
Other Income	23.54 Cr	38.89 Cr	56.52 Cr	66.94 Cr
Interest Received	18.61 Cr	23.5 Cr	35.41 Cr	47.28 Cr
Profit on sale of Fixed Assets	0	43 Lk	34 Lk	27 Lk
Profits on sale of Investments	0	90 Lk	0	0
Foreign Exchange Gains	71.94 Lk	10.98 Cr	13.82 Cr	11.31 Cr
Operating Profit	352.18 Cr	433.42 Cr	497.04 Cr	618.39 Cr
Interest	1.59 Cr	70 Lk	78 Lk	78 Lk
PBDT	350.59 Cr	432.72 Cr	496.26 Cr	617.61 Cr
Depreciation	36.97 Cr	46.9 Cr	44.99 Cr	53.44 Cr
Profit Before Taxation & Exceptional Items	313.62 Cr	385.82 Cr	451.27 Cr	564.17 Cr
Profit Before Tax	313.62 Cr	385.82 Cr	451.35 Cr	564.43 Cr
Provision for Tax	62.19 Cr	77.37 Cr	74.36 Cr	103.01 Cr
Current Income Tax	71.14 Cr	83.91 Cr	82.09 Cr	101.55 Cr
Deferred Tax	-8.96 Cr	-6.54 Cr	-7.73 Cr	1.46 Cr
Profit After Tax	251.43 Cr	308.45 Cr	376.99 Cr	461.42 Cr
Minority Interest	-9.16 Cr	-8.61 Cr	-73 Lk	-4.33 Cr
Consolidated Net Profit	242.27 Cr	299.84 Cr	376.26 Cr	457.09 Cr
Profit Balance B/F	675.17 Cr	914.41 Cr	1191.2 Cr	1539.79 Cr
Appropriations	917.44 Cr	1214.25 Cr	1567.46 Cr	1996.88 Cr
Other Appropriation	3.03 Cr	11.7 Cr	27.67 Cr	34.17 Cr
Equity Dividend %	150	200	225	250
Earnings Per Share	32.03	39.56	49.57	60.18
Adjusted EPS	32.03	39.56	49.57	60.18

STANDALONE PROFIT / LOSS FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	482.68 Cr	528.06 Cr	528.61 Cr	625.09 Cr
Sales	468.16 Cr	516.82 Cr	519.28 Cr	613.41 Cr
Processing Charges / Service Income	2.89 Cr	5.6 Cr	1.34 Cr	0
Net Sales	482.68 Cr	528.06 Cr	528.61 Cr	625.09 Cr
Increase/Decrease in Stock	-56.88 Lk	-9 Cr	-1.67 Cr	-43.68 Cr
Raw Material Consumed	195.4 Cr	213.65 Cr	199.73 Cr	248.9 Cr
Opening Raw Materials	6.48 Cr	8.7 Cr	14.48 Cr	18.71 Cr
Purchases Raw Materials	114.7 Cr	161.79 Cr	155.58 Cr	168.92 Cr
Closing Raw Materials	8.7 Cr	14.48 Cr	18.71 Cr	15.5 Cr
Other Direct Purchases / Brought in cost	82.92 Cr	57.64 Cr	48.38 Cr	76.77 Cr
Power & Fuel Cost	6.36 Cr	9.54 Cr	9.89 Cr	15.43 Cr
Electricity & Power	6.36 Cr	9.54 Cr	9.89 Cr	15.43 Cr
Employee Cost	26.03 Cr	29.91 Cr	35.81 Cr	37.18 Cr
Salaries, Wages & Bonus	18.9 Cr	23.44 Cr	27.08 Cr	30.89 Cr
Contributions to EPF & Pension Funds	1.66 Cr	1.93 Cr	1.45 Cr	1.58 Cr
Workmen and Staff Welfare Expenses	2.17 Cr	2.36 Cr	2.92 Cr	3.53 Cr
Other Manufacturing Expenses	27.14 Cr	34.68 Cr	42.18 Cr	54.17 Cr
Processing Charges	3.91 Cr	4.92 Cr	5.76 Cr	6.9 Cr
Repairs and Maintenance	3.06 Cr	4.75 Cr	4.64 Cr	16.52 Cr
General and Administration Expenses	6.52 Cr	7.97 Cr	8.8 Cr	18.24 Cr
Rent , Rates & Taxes	1.44 Cr	1.95 Cr	1.5 Cr	2.74 Cr
Insurance	54.5 Lk	63 Lk	64 Lk	79 Lk
Professional and legal fees	2.4 Cr	2.97 Cr	2.61 Cr	2.14 Cr
Traveling and conveyance	96.1 Lk	1.22 Cr	2.46 Cr	2.79 Cr
Selling and Distribution Expenses	2.77 Cr	12.23 Cr	3.91 Cr	1.88 Cr
Freight and Forwarding	2.77 Cr	12.23 Cr	3.91 Cr	1.88 Cr
Miscellaneous Expenses	5.11 Cr	9.6 Cr	10.58 Cr	5.89 Cr
Loss on disposal of fixed assets(net)	6.05 Lk	31 Lk	36 Lk	61 Lk
Loss on sale of non-trade current investments	0	14 Lk	0	0
Total Expenditure	268.76 Cr	308.58 Cr	309.23 Cr	338.01 Cr
Other Income	18.62 Cr	56.69 Cr	99.54 Cr	105.84 Cr
Interest Received	12.56 Cr	22.87 Cr	40.36 Cr	54.41 Cr
Dividend Received	3.05 Cr	23.05 Cr	46.18 Cr	37.54 Cr
Profit on sale of Fixed Assets	0	43 Lk	5 Lk	14 Lk
Profits on sale of Investments	86,000	5 Lk	6 Lk	44 Lk
Foreign Exchange Gains	17.23 Lk	8.33 Cr	9.39 Cr	8.34 Cr
Operating Profit	232.54 Cr	276.17 Cr	318.92 Cr	392.92 Cr
Interest	16.67 Lk	9 Lk	12 Lk	10 Lk
PBDT	232.38 Cr	276.08 Cr	318.8 Cr	392.82 Cr
Depreciation	22.44 Cr	25.77 Cr	25.65 Cr	27.08 Cr
Profit Before Taxation & Exceptional Items	209.94 Cr	250.31 Cr	293.15 Cr	365.74 Cr
Profit Before Tax	209.94 Cr	250.31 Cr	293.15 Cr	365.74 Cr
Provision for Tax	53.72 Cr	62.44 Cr	58.89 Cr	82.03 Cr
Current Income Tax	54.88 Cr	61.62 Cr	66.58 Cr	86.12 Cr
Deferred Tax	-1.17 Cr	82 Lk	-7.69 Cr	-4.09 Cr
Profit After Tax	156.22 Cr	187.87 Cr	234.26 Cr	283.71 Cr
Consolidated Net Profit	156.22 Cr	187.87 Cr	234.26 Cr	283.71 Cr
Profit Balance B/F	561.64 Cr	714.84 Cr	880.01 Cr	1083.95 Cr
Appropriations	717.86 Cr	902.71 Cr	1114.27 Cr	1367.66 Cr
Other Appropriation	3.03 Cr	11.35 Cr	15.16 Cr	18.98 Cr
Equity Dividend %	150	200	225	250
Earnings Per Share	20.65	24.79	30.86	37.35
Adjusted EPS	20.65	24.79	30.86	37.35

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR CAPLIN POINT LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	313.62 Cr	385.82 Cr	451.35 Cr	564.43 Cr
Adjustment	23.09 Cr	30.44 Cr	11.77 Cr	2.4 Cr
Changes In working Capital	-4.8 Cr	1.99 Cr	-103.75 Cr	-139.44 Cr
Cash Flow after changes in Working Capital	331.91 Cr	418.25 Cr	359.37 Cr	427.39 Cr
Cash Flow from Operating Activities	265.77 Cr	336.75 Cr	271.37 Cr	318.39 Cr
Cash Flow from Investing Activities	-5.36 Cr	-270.94 Cr	-217.58 Cr	-320.04 Cr
Cash Flow from Financing Activitie	-23.98 Cr	-40.71 Cr	-28.17 Cr	-38.07 Cr
Net Cash Inflow / Outflow	236.44 Cr	25.1 Cr	25.62 Cr	-39.72 Cr
Opening Cash & Cash Equivalents	220.77 Cr	435.72 Cr	150.76 Cr	177.56 Cr
Cash & Cash Equivalent on Amalgamation / Take over / Merger	0	0	0	-15 Lk
Effect of Foreign Exchange Fluctuations	-23.82 Lk	-9 Lk	1.18 Cr	86 Lk
Closing Cash & Cash Equivalent	456.96 Cr	460.73 Cr	177.56 Cr	138.55 Cr

STANDALONE CASH FLOW FOR CAPLIN POINT LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	209.94 Cr	250.31 Cr	293.15 Cr	365.74 Cr
Adjustment	7.75 Cr	-19.43 Cr	-59.57 Cr	-68.57 Cr
Changes In working Capital	131.87 Cr	62.07 Cr	-11.45 Cr	-99.07 Cr
Cash Flow after changes in Working Capital	349.55 Cr	292.95 Cr	222.13 Cr	198.1 Cr
Cash Flow from Operating Activities	294.64 Cr	230.97 Cr	157.1 Cr	111.01 Cr
Cash Flow from Investing Activities	16.28 Cr	-237.18 Cr	-86.67 Cr	-118.94 Cr
Cash Flow from Financing Activitie	-3.46 Cr	-22.76 Cr	-30.42 Cr	-34.26 Cr
Net Cash Inflow / Outflow	307.46 Cr	-28.97 Cr	40.01 Cr	-42.19 Cr
Opening Cash & Cash Equivalents	55.61 Cr	342.88 Cr	81.01 Cr	122.02 Cr
Effect of Foreign Exchange Fluctuations	-18.64 Lk	-9 Lk	1 Cr	81 Lk
Closing Cash & Cash Equivalent	362.88 Cr	313.82 Cr	122.02 Cr	80.64 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	89.71 Cr	89.74 Cr	89.76 Cr	89.77 Cr
Equity - Authorised	17 Cr	17 Cr	17 Cr	17 Cr
Equity - Issued	15.13 Cr	15.16 Cr	15.18 Cr	15.19 Cr
Equity Paid Up	15.13 Cr	15.16 Cr	15.18 Cr	15.19 Cr
Preference Capital Paid Up	74.58 Cr	74.58 Cr	74.58 Cr	74.58 Cr
Face Value	2	2	2	2
Total Reserves	1081.31 Cr	1385.24 Cr	1775.35 Cr	2211.72 Cr
Securities Premium	145.54 Cr	156.62 Cr	155.4 Cr	157.4 Cr
Capital Reserves	2.86 Cr	3.21 Cr	3.21 Cr	3.21 Cr
Profit & Loss Account Balance	914.41 Cr	1191.2 Cr	1539.79 Cr	1962.71 Cr
General Reserves	11.29 Cr	11.29 Cr	11.29 Cr	11.29 Cr
Reserve excluding Revaluation Reserve	1081.31 Cr	1385.24 Cr	1775.35 Cr	2211.72 Cr
Shareholder's Funds	1185.82 Cr	1483.93 Cr	1880.48 Cr	2315.71 Cr
Minority Interest	17.54 Cr	25.95 Cr	26.79 Cr	31.12 Cr
Term Loans - Banks	17.06 Cr	0	0	0
Deferred Tax Assets / Liabilities	1.16 Cr	-6.21 Cr	-13.83 Cr	-12.55 Cr
Deferred Tax Assets	19.81 Cr	28 Cr	29.63 Cr	24.67 Cr
Deferred Tax Liability	20.97 Cr	21.79 Cr	15.8 Cr	12.12 Cr
Other Long Term Liabilities	10.54 Cr	10.28 Cr	8.35 Cr	11.4 Cr
Long Term Provisions	5.7 Cr	8.48 Cr	7.78 Cr	8.61 Cr
Total Non-Current Liabilities	17.39 Cr	12.55 Cr	2.3 Cr	7.46 Cr
Trade Payables	88.5 Cr	163.18 Cr	164.37 Cr	209.41 Cr
Sundry Creditors	88.5 Cr	163.18 Cr	164.37 Cr	209.41 Cr
Other Current Liabilities	54.27 Cr	41.94 Cr	99.94 Cr	110.5 Cr
Advances received from customers	0	5.49 Cr	22.52 Cr	30.81 Cr
Short Term Borrowings	0	0	3.41 Cr	28 Lk
Short Term Provisions	8.5 Lk	2.56 Cr	28 Lk	11.09 Cr
Provision for post retirement benefits	8.5 Lk	0	0	0
Total Current Liabilities	142.85 Cr	207.68 Cr	268 Cr	331.28 Cr
Total Liabilities	1363.61 Cr	1730.11 Cr	2177.57 Cr	2685.57 Cr
Gross Block	422.57 Cr	445.74 Cr	480.32 Cr	702.31 Cr
Less: Accumulated Depreciation	117.17 Cr	159.17 Cr	200.51 Cr	249.65 Cr
Net Block	305.4 Cr	286.57 Cr	279.81 Cr	452.66 Cr
Capital Work in Progress	13.82 Cr	15.41 Cr	220.48 Cr	116.62 Cr
Non Current Investments	66.35 Lk	37.01 Cr	70.52 Cr	137.63 Cr
Long Term Investment	66.35 Lk	37.01 Cr	70.52 Cr	137.63 Cr
Quoted	66.35 Lk	60 Lk	74 Lk	1.09 Cr
Unquoted	0	36.41 Cr	69.78 Cr	136.54 Cr
Long Term Loans & Advances	7.92 Cr	89.9 Cr	51.68 Cr	78.31 Cr
Other Non Current Assets	0	1.08 Cr	39 Lk	7.43 Cr
Total Non-Current Assets	327.8 Cr	432.29 Cr	623.11 Cr	792.65 Cr
Currents Investments	10.54 Cr	51.97 Cr	159.17 Cr	237.98 Cr
Quoted	0	0	20.27 Cr	35.99 Cr
Unquoted	0	36.41 Cr	69.78 Cr	136.54 Cr
Inventories	179 Cr	227.31 Cr	288.22 Cr	363.04 Cr
Raw Materials	21.91 Cr	32.03 Cr	38.87 Cr	40.65 Cr
Work-in Progress	3.09 Cr	6.67 Cr	8.88 Cr	6.81 Cr
Finished Goods	4.73 Cr	17.91 Cr	13.84 Cr	18.56 Cr
Packing Materials	20.27 Cr	21.34 Cr	27.67 Cr	28.4 Cr
Stores and Spare	7.31 Cr	12.5 Cr	13.3 Cr	11.06 Cr
Sundry Debtors	279.36 Cr	320.06 Cr	394.06 Cr	542.72 Cr
Debtors more than Six months	0	0	3.78 Cr	82.77 Cr
Debtors Others	279.36 Cr	320.06 Cr	390.28 Cr	459.95 Cr
Cash and Bank	459.58 Cr	462.99 Cr	493.48 Cr	552.74 Cr
Cash in hand	2.66 Cr	2.54 Cr	1.49 Cr	14 Lk
Balances at Bank	456.92 Cr	460.45 Cr	491.99 Cr	552.6 Cr
Other Current Assets	20.25 Cr	13.61 Cr	27.32 Cr	50.43 Cr
Interest accrued on Investments	8.44 Cr	12.34 Cr	20.92 Cr	17.05 Cr
Prepaid Expenses	0	0	0	1.8 Cr
Short Term Loans and Advances	87.08 Cr	221.88 Cr	192.21 Cr	146.01 Cr
Advances recoverable in cash or in kind	41.94 Cr	59.46 Cr	70.19 Cr	62.4 Cr
Inter corporate deposits	0	118.5 Cr	51.01 Cr	0
Total Current Assets	1035.81 Cr	1297.82 Cr	1554.46 Cr	1892.92 Cr
Net Current Assets (Including Current Investments)	892.95 Cr	1090.14 Cr	1286.46 Cr	1561.64 Cr
Total Assets	1363.61 Cr	1730.11 Cr	2177.57 Cr	2685.57 Cr
Contingent Liabilities	1.02 Cr	71 Lk	64 Lk	64 Lk
Total Debt	17.07 Cr	50 Lk	3.41 Cr	28 Lk
Book Value	144.95	184.75	235.91	293.21
Adjusted Book Value	144.95	184.75	235.91	293.21

STANDALONE BALANCE SHEET FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	15.13 Cr	15.16 Cr	15.18 Cr	15.19 Cr
Equity - Authorised	17 Cr	17 Cr	17 Cr	17 Cr
Equity - Issued	15.13 Cr	15.16 Cr	15.18 Cr	15.19 Cr
Equity Paid Up	15.13 Cr	15.16 Cr	15.18 Cr	15.19 Cr
Face Value	2	2	2	2
Total Reserves	728.75 Cr	906.53 Cr	1109.36 Cr	1360.74 Cr
Securities Premium	2.12 Cr	14.63 Cr	13.41 Cr	15.41 Cr
Capital Reserves	40.98 Lk	41 Lk	41 Lk	41 Lk
Profit & Loss Account Balance	714.84 Cr	880.01 Cr	1083.95 Cr	1333.49 Cr
General Reserves	11.29 Cr	11.29 Cr	11.29 Cr	11.29 Cr
Reserve excluding Revaluation Reserve	728.75 Cr	906.53 Cr	1109.36 Cr	1360.74 Cr
Shareholder's Funds	758.67 Cr	930.65 Cr	1139.91 Cr	1390.15 Cr
Deferred Tax Assets / Liabilities	20.97 Cr	21.79 Cr	14.14 Cr	10 Cr
Deferred Tax Liability	20.97 Cr	21.79 Cr	14.14 Cr	10 Cr
Other Long Term Liabilities	4.02 Cr	2.84 Cr	2.28 Cr	2.86 Cr
Total Non-Current Liabilities	25 Cr	24.63 Cr	16.42 Cr	12.86 Cr
Trade Payables	70.1 Cr	72.26 Cr	81.42 Cr	78.62 Cr
Sundry Creditors	70.1 Cr	72.26 Cr	81.42 Cr	78.62 Cr
Other Current Liabilities	7.23 Cr	25.42 Cr	65.26 Cr	36.26 Cr
Advances received from customers	0	19.61 Cr	43.22 Cr	14.56 Cr
Short Term Provisions	0	1.2 Cr	17 Lk	4.42 Cr
Total Current Liabilities	77.33 Cr	98.88 Cr	146.85 Cr	119.3 Cr
Total Liabilities	861 Cr	1054.16 Cr	1303.18 Cr	1522.31 Cr
Gross Block	266.22 Cr	268.64 Cr	285.13 Cr	318.45 Cr
Less: Accumulated Depreciation	83.53 Cr	106.18 Cr	128.28 Cr	152.66 Cr
Net Block	182.69 Cr	162.46 Cr	156.85 Cr	165.79 Cr
Capital Work in Progress	1.36 Cr	1.73 Cr	42.68 Cr	27.75 Cr
Non Current Investments	138.64 Cr	212.73 Cr	274.97 Cr	346.17 Cr
Long Term Investment	138.64 Cr	212.73 Cr	274.97 Cr	346.17 Cr
Quoted	66.35 Lk	60 Lk	74 Lk	1.09 Cr
Unquoted	137.98 Cr	212.13 Cr	274.23 Cr	345.08 Cr
Long Term Loans & Advances	5.66 Cr	70.7 Cr	164.7 Cr	272.07 Cr
Other Non Current Assets	0	0	0	7.43 Cr
Total Non-Current Assets	328.36 Cr	448.49 Cr	639.2 Cr	819.21 Cr
Currents Investments	10.54 Cr	51.97 Cr	159.17 Cr	237.98 Cr
Quoted	0	0	20.27 Cr	35.99 Cr
Unquoted	137.98 Cr	212.13 Cr	274.23 Cr	345.08 Cr
Inventories	24.87 Cr	42.81 Cr	51.53 Cr	86.25 Cr
Raw Materials	8.7 Cr	14.48 Cr	18.71 Cr	15.5 Cr
Work-in Progress	1.58 Cr	2.64 Cr	3.94 Cr	3.2 Cr
Finished Goods	4.36 Cr	14.37 Cr	16.29 Cr	47.8 Cr
Packing Materials	5.09 Cr	6.55 Cr	9.35 Cr	5.43 Cr
Stores and Spare	56.76 Lk	2.27 Cr	2.29 Cr	46 Lk
Sundry Debtors	98.46 Cr	53.73 Cr	88.24 Cr	128.67 Cr
Debtors more than Six months	0	0	0	24 Lk
Debtors Others	98.46 Cr	53.73 Cr	88.24 Cr	128.43 Cr
Cash and Bank	365.5 Cr	316.08 Cr	271.38 Cr	215.78 Cr
Cash in hand	4.58 Lk	6 Lk	5 Lk	4 Lk
Balances at Bank	365.45 Cr	316.02 Cr	271.33 Cr	215.74 Cr
Other Current Assets	18.32 Cr	11.97 Cr	21.42 Cr	2.27 Cr
Interest accrued on Investments	8.18 Cr	11.52 Cr	20.06 Cr	60 Lk
Prepaid Expenses	0	0	0	1 Cr
Short Term Loans and Advances	14.98 Cr	129.11 Cr	72.24 Cr	32.15 Cr
Advances recoverable in cash or in kind	2.6 Cr	1.98 Cr	3.19 Cr	2.22 Cr
Inter corporate deposits	0	118.5 Cr	51.01 Cr	13.01 Cr
Total Current Assets	532.65 Cr	605.67 Cr	663.98 Cr	703.1 Cr
Net Current Assets (Including Current Investments)	455.32 Cr	506.79 Cr	517.13 Cr	583.8 Cr
Total Assets	861 Cr	1054.16 Cr	1303.18 Cr	1522.31 Cr
Contingent Liabilities	1.02 Cr	71 Lk	64 Lk	64 Lk
Total Debt	1.19 Lk	0	0	0
Book Value	98.34	121.6	148.16	181.16
Adjusted Book Value	98.34	121.6	148.16	181.16

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	32.03	39.56	49.57	60.18
CEPS(Rs)	38.13	46.88	55.6	67.79
DPS(Rs)	3	4	4.5	5
Book NAV/Share(Rs)	144.95	184.75	235.91	293.21
Tax Rate(%)	19.83	20.05	16.48	18.25
Margin Ratios
Core EBITDA Margin(%)	30.97	31.08	30.03	32.55
EBIT Margin(%)	29.7	30.45	30.83	33.36
Pre Tax Margin(%)	29.55	30.39	30.77	33.32
PAT Margin (%)	23.69	24.3	25.7	27.24
Cash Profit Margin (%)	27.17	27.99	28.77	30.39
Performance Ratios
ROA(%)	20.2	19.94	19.29	18.98
ROE(%)	25.65	24.71	23.68	22.97
ROCE(%)	28.82	28.77	26.85	26.92
Asset Turnover(x)	0.85	0.82	0.75	0.7
Sales/Fixed Asset(x)	2.73	2.92	3.17	2.87
Working Capital/Sales(x)	1.19	1.16	1.14	1.08
Efficiency Ratios
Fixed Capital/Sales(x)	0.37	0.34	0.32	0.35
Receivable days	87.41	86.18	88.48	100.92
Inventory Days	71.75	58.42	64.15	70.16
Payable days	43.93	82.39	88.14	91.22
Valuation Parameters
PER(x)	12.62	17.19	12.04	21.89
PCE(x)	10.6	14.5	10.73	19.43
Price/Book(x)	2.79	3.68	2.53	4.49
Yield(%)	0.74	0.59	0.75	0.38
EV/Net Sales(x)	2.53	3.75	2.8	5.62
EV/Core EBITDA(x)	7.64	11	8.28	15.41
EV/EBIT(x)	8.53	12.33	9.1	16.86
EV/CE(x)	1.97	2.75	1.89	4.11
M Cap / Sales	2.88	4.06	3.09	5.91
Growth Ratio
Net Sales Growth(%)	22.95	19.61	15.54	15.5
Core EBITDA Growth(%)	16.85	23.07	14.68	24.41
EBIT Growth(%)	16.84	22.62	16.97	25.01
PAT Growth(%)	16.9	22.68	22.22	22.4
EPS Growth(%)	12.68	23.52	25.32	21.4
Financial Stability Ratios
Total Debt/Equity(x)	0.01	0	0	0
Current Ratio(x)	7.25	6.25	5.8	5.71
Quick Ratio(x)	6	5.15	4.72	4.62
Interest Cover(x)	198.29	552.17	579.65	724.63
Total Debt/Mcap(x)	0.01	0	0	0

FINANCIAL RATIOS (STANDALONE) FOR CAPLIN POINT LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	20.65	24.79	30.86	37.35
CEPS(Rs)	23.62	28.18	34.24	40.92
DPS(Rs)	3	4	4.5	5
Book NAV/Share(Rs)	98.34	121.6	148.16	181.16
Tax Rate(%)	25.59	24.95	20.09	22.43
Margin Ratios
Core EBITDA Margin(%)	44.32	41.56	41.5	45.93
EBIT Margin(%)	43.53	47.42	55.48	58.53
Pre Tax Margin(%)	43.49	47.4	55.46	58.51
PAT Margin (%)	32.37	35.58	44.32	45.39
Cash Profit Margin (%)	37.01	40.46	49.17	49.72
Performance Ratios
ROA(%)	20.13	19.62	19.87	20.08
ROE(%)	23.42	22.56	22.97	22.69
ROCE(%)	30.92	29.64	28.33	28.92
Asset Turnover(x)	0.62	0.55	0.45	0.44
Sales/Fixed Asset(x)	1.95	1.97	1.91	2.07
Working Capital/Sales(x)	1.06	1.04	1.02	1.07
Efficiency Ratios
Fixed Capital/Sales(x)	0.51	0.51	0.52	0.48
Receivable days	120.02	52.6	49.01	63.33
Inventory Days	17.86	23.39	32.57	40.23
Payable days	78.8	126.96	134.94	132.73
Valuation Parameters
PER(x)	19.57	27.43	19.33	35.26
PCE(x)	17.11	24.12	17.43	32.19
Price/Book(x)	4.11	5.59	4.03	7.27
Yield(%)	0.74	0.59	0.75	0.38
EV/Net Sales(x)	5.58	9.16	8.05	15.66
EV/Core EBITDA(x)	11.57	17.52	13.35	24.91
EV/EBIT(x)	12.81	19.32	14.52	26.76
EV/CE(x)	3.13	4.59	3.27	7.04
M Cap / Sales	6.33	9.76	8.57	16.01
Growth Ratio
Net Sales Growth(%)	-8.55	9.4	0.1	18.25
Core EBITDA Growth(%)	-14.81	18.76	15.48	23.2
EBIT Growth(%)	-17.06	19.18	17.12	24.75
PAT Growth(%)	-20.96	20.25	24.69	21.11
EPS Growth(%)	-20.96	20.01	24.53	21.03
Financial Stability Ratios
Current Ratio(x)	6.89	6.13	4.52	5.89
Quick Ratio(x)	6.57	5.69	4.17	5.17
Interest Cover(x)	1260.36	2782.22	2443.92	3658.4

SHARE HOLDING PATTERN FOR CAPLIN POINT LABORATORIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	68.88	68.88	68.80	70.66	70.63	70.63	70.62	70.62	70.56	70.56
FII %	2.03	2.15	2.24	2.36	2.68	3.08	2.83	3.32	3.37	3.69
DII %	0.05	0.07	0.00	0.07	0.21	0.02	0.02	0.02	0.09	0.06
Public %	27.97	27.85	27.84	26.34	26.42	26.08	26.10	24.95	24.57	23.91

PEER COMPARISON FOR CAPLIN POINT LABORATORIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR CAPLIN POINT

Exchange Date	Purpose	Book Closure Dates
BSE 30-Oct-2024	Board Meeting - Quarterly Results	07-Nov-2024
BSE 08-Aug-2024	Book Closure - Rs.2.5000 per share(125%)Final Dividend & A.G.M.	24-Sep-2024 30-Sep-2024
BSE 07-Aug-2024	Dividend - Rs.2.5000 per share(125%)Final Dividend
BSE 07-Aug-2024	AGM - Inter-alia, recommended/ approved the following: 1. Recommended a Final Dividend of INR. 2.5 (125%) per equity share of Rs.2 each for the financial year ended March 31, 2024. This shall be paid subject to approval of the shareholders at the forthcoming Annual General Meeting. 2. Approved the re-appointment of Dr Sridhar Ganesan as Managing Director for further period of two years w.e.f August 25, ...	30-Sep-2024
BSE 31-Jul-2024	Board Meeting - A.G.M. & Quarterly Results & Final Dividend	07-Aug-2024
BSE 31-May-2024	Dividend - Rs.2.5000 per share(125%)Interim Dividend
BSE 09-May-2024	Board Meeting - Audited Results & Interim Dividend	16-May-2024
BSE 30-Jan-2024	Board Meeting - Quarterly Results	09-Feb-2024
BSE 01-Nov-2023	Board Meeting - Quarterly Results	09-Nov-2023
BSE 08-Aug-2023	Book Closure - Rs.2.5000 per share(125%)Final Dividend & A.G.M.	15-Sep-2023 21-Sep-2023
BSE 08-Aug-2023	AGM - Rs.2.5000 per share(125%)Final Dividend & A.G.M.	21-Sep-2023 21-Sep-2023
BSE 07-Aug-2023	Dividend - Rs.2.5000 per share(125%)Final Dividend
BSE 31-Jul-2023	Board Meeting - Final Dividend & Quarterly Results & A.G.M.	07-Aug-2023
BSE 09-Jun-2023	Dividend - Rs.2.0000 per share(100%)Interim Dividend
BSE 23-May-2023	Board Meeting - Audited Results (Revised) & Quarterly Results (Revised) & Interim Dividend	27-May-2023
BSE 15-May-2023	Board Meeting - Audited Results & Interim Dividend & Quarterly Results	24-May-2023
BSE 30-Jan-2023	Board Meeting - Quarterly Results	11-Feb-2023
BSE 02-Nov-2022	Board Meeting - Quarterly Results	12-Nov-2022
BSE 05-Sep-2022	Book Closure - Rs.2.0000 per share(100%)Final Dividend & A.G.M.	23-Sep-2022 29-Sep-2022
BSE 05-Sep-2022	AGM - Rs.2.0000 per share(100%)Final Dividend & A.G.M.	29-Sep-2022 29-Sep-2022
BSE 05-Aug-2022	Dividend - Rs.2.0000 per share(100%)Final Dividend
BSE 28-Jul-2022	Board Meeting - Quarterly Results & Final Dividend	05-Aug-2022
BSE 23-May-2022	Dividend - Rs.2.0000 per share(100%)Interim Dividend
BSE 05-May-2022	Board Meeting - Audited Results & Interim Dividend	12-May-2022
BSE 28-Jan-2022	Board Meeting - Quarterly Results	03-Feb-2022
BSE 27-Oct-2021	Board Meeting - Quarterly Results	02-Nov-2021
BSE 02-Sep-2021	AGM - Rs.1.5000 per share(75%)Final Dividend & A.G.M.	28-Sep-2021 28-Sep-2021
BSE 02-Sep-2021	Book Closure - Rs.1.5000 per share(75%)Final Dividend & A.G.M.	22-Sep-2021 28-Sep-2021

CORPORATE ANNOUNCEMENTS FOR CAPLIN POINT

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation regarding post-results conference call with the analysts / fund houses/ investors is enclosed
BSE 30-Oct-2024	Intimation FILE	Board Meeting Intimation for Intimation Of Board Meeting CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve Un-audited Financial Results of the Company for the quarter and half-year ended September 30 2024 (both standalone and consolidated)
BSE 23-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of Loss of Share Certificates are attached herewith
BSE 10-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We submit herewith a Certificate under Regulation 74(5) of the SEBI (DP) Regulations 2018 received from RTA of the Company for the quarter ended September 30 2024.
BSE 01-Oct-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report The Voting results along with the scrutinizers report is enclosed
BSE 30-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Details of appointment of Mr. R Vijayaraghavan as an Independent Director of the Company is attached herewith
BSE 30-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Details of Proceedings of the Thirty Third Annual General Meeting of the Company is attached herewith
BSE 30-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of loss of share certificate is attached herewith
BSE 26-Sep-2024	Intimation FILE	Closure of Trading Window Details regarding the closure of trading window is attached herewith
BSE 19-Sep-2024	General Announcements FILE	Issuance Of Bonus Equity Shares By Caplin Point Far East Limited - Hong Kong Wholly Owned Material Subsidiary Of The Company The details of the Bonus Shares issued by the Caplin Point Far East Limited - Hong Kong is enclosed.
BSE 16-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of loss of share certificates are attached herewith
BSE 06-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper advertisement for Book-Closure and e-voting process for the Annual General Meeting.
BSE 06-Sep-2024	General Announcements FILE	Notice Of 33Rd AGM Of The Company To Be Held On September 30 2024 Through VC/OAVM Notice of the 33rd AGM along with the Annual report of the company is enclosed herewith
BSE 06-Sep-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) The Business Responsibility and Sustainability Report for the FY 2023-24 is enclosed.
BSE 06-Sep-2024	General Announcements FILE	Reg. 34 (1) Annual Report. The Annual Report for the financial year 2023-2024 is enclosed herewith
BSE 06-Sep-2024	General Announcements FILE	Reply To Clarification Sought By Exchange For Spurt In Volume In Shares Of The Company Reply Letter is attached herewith.
BSE 06-Sep-2024	General -	Clarification sought from Caplin Point Laboratories Ltd The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 6 2024 with reference to Movement in Volume.The reply is awaited.
BSE 29-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Details regarding Analyst(s)/ Investors visiting the plant of Caplin Steriles Limited (Companys Subsidiary) is enclosed herewith.
BSE 24-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of loss of share certificates are attached herewith.
BSE 16-Aug-2024	General Announcements FILE	Completion Of Inspection By ANVISA - Brazil This is to inform you that ANVISA - Brazil conducted inspection at the facility of Caplin Steriles limited the companys subsidiary and concluded with zero observations.
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of the Earnings Call - Q1 -FY 2024-25 is attached
BSE 10-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details regarding loss of share certificates are attached herewith.
BSE 09-Aug-2024	General Announcements FILE	Update Completion of unannounced US FDA inspection at the facility of Caplin Steriles Limited (Companys Subsidiary)
BSE 09-Aug-2024	General Announcements FILE	Press Release The company has been recognized in Forbes Asias "200 Best under Billion" list for the year 2024. Press Release on the same is enclosed.
BSE 08-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Advertisement with respect to Financial Results in Financial Express (English Newspaper) and Maalai Malar (Tamil Newspaper) is attached.
BSE 08-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Attached the Press Release for Grant of USFDA Approval.
BSE 07-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome The weblink for the Earnings call is enclosed herewith.
BSE 07-Aug-2024	Outcome FILE	Corporate Action-Board approves Dividend The Board has recommended Final Dividend of INR 2.5 per equity shares subject to the approval of shareholders
BSE 07-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate The details of re-appointment of Managing Director is attached herewith.
BSE 07-Aug-2024	Outcome FILE	Financial Results For The Quarter Ended June 30 2024 The financial results for the quarter ended June 30 2024 and the other items are enclosed

INSIDER TRADING FOR CAPLIN POINT

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 23-Mar-2023 23-Mar-2023	Buy Gift	898,790 @ 0.00 (1.19 %)	P Vijayalakshmi
BSE 23-Nov-2021 23-Nov-2021	Sell Market	5,000 @ 0.00 (0.00 %)	Sathish Krishnan
BSE 22-Nov-2021 22-Nov-2021	Sell Market	2,000 @ 0.00 (0.00 %)	Arulsudar Natrajan
BSE 22-Nov-2021 22-Nov-2021	Sell Market	1,500 @ 0.00 (0.00 %)	Arulsudar Natrajan
BSE 17-Nov-2021 17-Nov-2021	Sell Market	4,900 @ 0.00 (0.00 %)	Subramanian Narayanswamy
BSE 17-Nov-2021 17-Nov-2021	Sell Market	100 @ 0.00 (0.00 %)	Subramanian Narayanaswamy
BSE 17-Nov-2021 17-Nov-2021	Sell Market	1,500 @ 0.00 (0.00 %)	Arulsudar Natrajan
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Justin Babu J
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	6,667 @ 0.00 (0.00 %)	Mohith Santoshkumar
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	1,667 @ 0.00 (0.00 %)	Nagamani R
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	4,167 @ 0.00 (0.00 %)	Anand G K
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Neelakandan
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	2,500 @ 0.00 (0.00 %)	Balaji G
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	3,000 @ 0.00 (0.00 %)	Dinesh R
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	2,500 @ 0.00 (0.00 %)	Dinesh T
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,500 @ 0.00 (0.00 %)	Harikishan K
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Arul Sudar
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	1,667 @ 0.00 (0.00 %)	Prabakaran T
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	3,125 @ 0.00 (0.00 %)	Pramoth Narasimmhan
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	3,333 @ 0.00 (0.00 %)	Pravin Babu S T
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Subramanian Narayanswamy
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	2,500 @ 0.00 (0.00 %)	Venkataraju M P
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	2,500 @ 0.00 (0.00 %)	Vijayarangam R M
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	3,000 @ 0.00 (0.00 %)	Umapathy V
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	8,333 @ 0.00 (0.00 %)	Umesh Shetty
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	2,500 @ 0.00 (0.00 %)	Vamsee Krishna Tata
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Sathyanarayanan M
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Satish Krishnan
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	5,000 @ 0.00 (0.00 %)	Satish Kumar Rajendran
BSE 02-Nov-2021 02-Nov-2021	Buy ESOP	4,167 @ 0.00 (0.00 %)	Satish Kumar S

BULK BLOCK DEALS FOR CAPLIN POINT LABORATORIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Bulk Block details found

DIVIDEND BY CAPLIN POINT LABORATORIES LIMITED

Ex Dividend Date	Dividend Type	Dividend
23-Sep-2024	DIVIDEND	2.5
31-May-2024	INTERIM DIVIDEND	2.5
14-Sep-2023	DIVIDEND	2.5
09-Jun-2023	INTERIM DIVIDEND	2
21-Sep-2022	DIVIDEND	2
23-May-2022	INTERIM DIVIDEND	2
20-Sep-2021	DIVIDEND	1.5
18-May-2021	INTERIM DIVIDEND	1.5